Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study.

Carolina BolognaPasquale MadonnaEduardo Pone

Published in: Journal of clinical medicine (2021)

A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
sleep quality
peritoneal dialysis
physical activity
stem cells
patient reported
smoking cessation